Weak and transient carbohydrate–protein interactions hinder the detection of carbohydrate‐binding proteins (CBPs) in native settings. Here, we introduce carbohydrate‐directed labeling probes (CDLPs), modular ligand‐directed covalent probes composed of a glycan ligand, an acyl‐transfer electrophile, and a distal azide handle. Glycan binding positions the electrophile for proximity‐enhanced, glycan‐releasing acyl transfer, leaving an azide‐bearing acyl tag on the protein. Benchmark CDLPs capture carbohydrate–protein interactions with monovalent KD values extending into the millimolar range. In Daudi B cells, a 6′‐sialyllactose CDLP preferentially captures CD22 (Siglec‐2), demonstrating glycan‐dependent labeling in live cells. Quantitative chemoproteomics using 6′‐sialyllactose‐ and lactose‐CDLPs yields complementary competition‐sensitive CDLP‐capture profiles (6′SL‐CDLP: 95; Lac‐CDLP: 113; 21 shared), including canonical CBPs, glycan‐processing proteins, and candidate proteins lacking prior glycan‐related annotations. CDLPs provide an accessible, UV‐independent route to durable covalent readouts for targeted validation and proteome‐scale candidate discovery.
Weak and transient carbohydrate–protein interactions hinder the detection of carbohydrate‐binding proteins (CBPs) in native settings. Here, we introduce carbohydrate‐directed labeling probes (CDLPs), modular ligand‐directed covalent probes composed of a glycan ligand, an acyl‐transfer electrophile, and a distal azide handle. Glycan binding positions the electrophile for proximity‐enhanced, glycan‐releasing acyl transfer, leaving an azide‐bearing acyl tag on the protein. Benchmark CDLPs capture carbohydrate–protein interactions with monovalent KD values extending into the millimolar range. In Daudi B cells, a 6′‐sialyllactose CDLP preferentially captures CD22 (Siglec‐2), demonstrating glycan‐dependent labeling in live cells. Quantitative chemoproteomics using 6′‐sialyllactose‐ and lactose‐CDLPs yields complementary competition‐sensitive CDLP‐capture profiles (6′SL‐CDLP: 95; Lac‐CDLP: 113; 21 shared), including canonical CBPs, glycan‐processing proteins, and candidate proteins lacking prior glycan‐related annotations. CDLPs provide an accessible, UV‐independent route to durable covalent readouts for targeted validation and proteome‐scale candidate discovery.
The ICAM-1-derived cIBR peptide selectively binds to the I-domain of LFA-1, a receptor highly expressed on leukemia T cells; thus, the MTX-cIBR conjugate can be used to target methotrexate (MTX) to leukemic T cells and reduce its off-target toxicity. However, the uptake, biological mechanism, and selectivity of MTX-cIBR compared with unconjugated MTX remain unclear. Therefore, this study is aimed at evaluating the uptake, cytotoxicity, selectivity, apoptosis, cell cycle effects, and DHFR-related activity of MTX-cIBR in leukemia T cells compared with unconjugated MTX. MTX-cIBR exhibited cytotoxic activity comparable to MTX in LFA-1-expressing MOLT-4 cells but showed lower toxicity toward LFA-1-negative K562 cells, indicating improved selectivity. MTX uptake occurred through RFC and mFBP transport systems, whereas MTX-cIBR no longer depended on these pathways, suggesting altered cellular uptake after conjugation with cIBR by utilizing the LFA-1 receptor. Both compounds predominantly induced apoptosis with minimal necrotic cell populations. MTX induced S-phase arrest at lower concentrations and G2/M induced arrest at higher concentrations, whereas MTX-cIBR consistently promoted S-phase accumulation. In addition, MTX and MTX-cIBR downregulated the expression of DHFR, FPGS, and TYMS in MOLT-4 cells. Computational analyses further demonstrated that MTX exhibited lower binding free energy (ΔG) and greater binding stability toward DHFR than MTX-cIBR. These findings suggest that MTX-cIBR retains selective cytotoxic activity toward LFA-1-expressing leukemia T cells through altered cellular uptake and exhibits different interaction characteristics with DHFR compared with unconjugated MTX.